[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351513-105":59,"doc-detail-351513-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","spatial-proteomics-of-breast-ductal-carcinoma-in-situ-reveal-distinct-regional-differences","Spatial proteomics of breast ductal carcinoma in situ reveal distinct regional differences","","Breast ductal carcinoma in situ (DCIS) is a common non-invasive finding that can progress to invasive breast cancer, making risk stratification and microenvironment understanding essential. A subset of 103 primary DCIS specimens with known outcomes was analyzed using a multiplexed proteomic platform (Nanostring GeoMx) to quantify 53 antigens across 1226 filtered spatial ROIs. Two predominant DCIS subgroups emerged (ER high/HER2 low and ER low/HER2 high), with protein differences across benign versus DCIS, ER status, and intra-epithelial regions. Several immune-related antigens in DCIS epithelium (CD127, CD8, PD-L2) associated with invasive progression, and matched ipsilateral events showed hormonal therapy effects on subsequent cancer phenotype.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/spatial-proteomics-of-breast-ductal-carcinoma-in-situ-reveal-distinct-regional-differences/351513/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/spatial-proteomics-of-breast-ductal-carcinoma-in-situ-reveal-distinct-regional-differences/351513.png","ImageObject",300,407,{"name":92,"@type":93},"Fahsai","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What spatial proteomics platform and measurements were used to analyze the DCIS specimens?","Question",{"text":113,"@type":114},"The study used Nanostring GeoMx, a multiplexed proteomic platform, to quantitatively measure 53 antigens across spatial regions of interest after filtering.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What two predominant DCIS subgroups were identified in the data?",{"text":118,"@type":114},"Two main subgroups were identified: ER high/HER2 low and ER low/HER2 high.",{"name":120,"@type":111,"acceptedAnswer":121},"Which immune-related antigens within DCIS epithelium were linked to invasive progression?",{"text":122,"@type":114},"CD127, CD8, and PD-L2 were identified in DCIS epithelium and associated with invasive progression.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},351513,1790283333,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},549768702563,"https://ap-avatar.wpscdn.com/avatar/8000c4aa63b76e948b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786536092046926083","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nSpatial proteomics of breast ductal carcinoma in situ reveal distinct regional differences  \nJeffrey R. Marks1􀀍, Yanwan Dai2, Lorraine M. King1, Lunden Simpson1, Allison Hall3, Rachel E. Factor3, Smita K. Nair1, Jadee L. Neff3, Alexander B. Sibley2, Kouros Owzar2,4 &  \nE. Shelley Hwang1  \nBreast ductal carcinoma in situ is a common non-invasive clinical finding that can progress to invasive breast cancer (IBC). Spatial proteomics can provide an additional dimension to our understanding of this disease and its capacity to progress. A subset (n = 103 patients) of a previously established cohort of primary DCIS specimens with known clinical outcomes was analyzed using a multiplexed proteomic platform (Nanostring GeoMx) for simultaneous quantitative measurement of 53 antigens. 1262 spatially distinct regions of interest (ROIs) (1226 ROIs after filtering) were collected, including inside DCIS epithelium, adjacent stroma, co-existing benign breast epithelium, and biopsy sites. We identified two predominant subgroups of DCIS, ER high/HER2 low and ER low/HER2 high. Levels of tumor associated proteins varied between benign and DCIS, between ER + and ER-patients, and between different regions within the DCIS epithelium. In addition, we identified several immunerelated antigens (CD127, CD8, and PD-L2) within the DCIS epithelium that are associated with invasive progression. Comparison of antigen levels in matched ipsilateral breast events (both DCIS recurrences and IBC) demonstrates an effect of hormonal therapy on the phenotype of subsequent cancers. This study adds a spatially resolved proteomic dimension to our understanding of DCIS, its microenvironment, and its propensity to progress to IBC.  \nDuctal carcinoma in situ (DCIS) of the breast is a common diagnosis typically detected by its characteristic calcifications on mammography. This non-invasive epithelial proliferation does have the potential to become invasive and thus is typically removed surgically with adjuvant radiotherapy delivered to improve local control of the disease. However, many of these lesions do not progress1–3 and this has prompted a series of clinical trials of active monitoring, particularly for DCIS that has a low or intermediate histologic grade4–6. Complementary to these trials are efforts to identify DCIS that are most or least likely to progress, either with or without therapy7–11. We previously reported an expression signature derived from RNA sequencing of the epithelium and nearby stroma containing genes expressed from both types of cells that discriminates recurrent (either DCIS or invasive disease) from non-recurrent patients12. We have also reported on a signature derived from a mass spectrometrybased metal tagged multiplexed antibody approach (MIBI) on a small subset of samples, indicating that spatial features are important in identifying high risk DCIS13.  \nSpatial detection methods are rapidly advancing and becoming more widely available for investigational purposes. While single-cell RNA techniques measure a large fraction of the genome, protein detection methods are constrained by the necessity of using a series of specific affinity reagents, i.e., antibodies. In this study, we analyzed a series of patients on which we established our RNA expression signature using a commercial multiplexed spatial protein detection platform, Nanostring GeoMx, at a resolution that fills an important gap between bulk sequencing and single cell methods. Moreover, evaluation of protein expression provides data that are more proximal to tumor biology than transcriptomic technologies. The study had two aims: (1) determine how protein expression differs according to distinct spatial locations within the DCIS microenvironment and (2) determine whether DCIS protein expression is associated with disease progression.  \n1Department of Surgery, Duke University School of Medicine, Durham, NC 277","cbCaiaGorbYgP2YR","https://ap.wps.com/l/cbCaiaGorbYgP2YR","pdf",3458074,13,"English","# Abstract\n# Methods\n## Clinical materials","[{\"question\":\"What spatial proteomics platform and measurements were used to analyze the DCIS specimens?\",\"answer\":\"The study used Nanostring GeoMx, a multiplexed proteomic platform, to quantitatively measure 53 antigens across spatial regions of interest after filtering.\"},{\"question\":\"What two predominant DCIS subgroups were identified in the data?\",\"answer\":\"Two main subgroups were identified: ER high/HER2 low and ER low/HER2 high.\"},{\"question\":\"Which immune-related antigens within DCIS epithelium were linked to invasive progression?\",\"answer\":\"CD127, CD8, and PD-L2 were identified in DCIS epithelium and associated with invasive progression.\"}]","Spatial proteomics of breast ductal carcinoma in situ reveal distinct regional differences | PDF",1790094510,33,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b692841ce29950fab2c29f73c9e1bb0b.webp",983,1291,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ea2725f3844a05f73791744e09268bbb.webp",982,1290,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5b4fcf2cfac05292cecc3d67090ae356.webp",981,1289,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f65097627f6e9201b6438b5e42d9345.webp",980,1287]